Lanthio Pharma licenses drug to Tarix

21 February 2012

Lanthio Pharma, a privately-held Dutch peptide drug company, says that it has granted USA-based Tarix Pharmaceuticals exclusive license to its lanthionine-stabilized angiotensin-(1-7) agonistic peptide, in return for milestone payments and royalties. Tarix will finance further product development. Further commercial terms were not disclosed.

Lanthionine-stabilized angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. It is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep technology. The compound is stable and resistant to angiotensin-converting enzyme. Additionally, it has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).

Early revenue opportunity for Lanthio

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical